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Abstract: Immunomodulation is the process of alteration in immune response due to foreign 
intrusion of molecules inside the body. Along with the available drugs, a large number of herbal 
drugs are promoted in traditional Indian treatments, for their immunomodulating activity. Natural 
coumarinolignoids isolated from the seeds of Cleome viscose have been recognized as having 
hepatoprotective action and have recently been tested preclinically for their immunomodulatory 
activity affecting both cell-mediated and humoral immune response. To explore the immuno-
modulatory compound from derivatives of coumarinolignoids, a quantitative structure activity 
relationship (QSAR) and molecular docking studies were performed. Theoretical results are in 
accord with the in vivo experimental data studied on Swiss albino mice. Immunostimulatory 
activity was predicted through QSAR model, developed by forward feed multiple linear regres-
sion method with leave-one-out approach. Relationship correlating measure of QSAR model 
was 99% (R2 = 0.99) and predictive accuracy was 96% (RCV2 = 0.96). QSAR studies indicate 
that dipole moment, steric energy, amide group count, lambda max (UV-visible), and molar 
refractivity correlates well with biological activity, while decrease in dipole moment, steric 
energy, and molar refractivity has negative correlation. Docking studies also showed strong 
binding affinity to immunomodulatory receptors.
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Immunomodulation is the process of alteration in immune response due to foreign 
intrusion of molecules inside the body. It can be either immunostimulative or immu-
nosuppressive. Along with the available drugs, a large number of herbal drugs are 
mentioned in Ayurveda (a traditional system of Indian medicine), for their immuno-
modulating activity.1–2 In the past, living and attenuated microorganisms’ autologous 
and heterologous proteins and injections of animal organ preparations were used with 
the aim of restoring an impaired defense mechanism. At present thymus peptides and 
other biological response modifiers (BRM) (eg, interferon, interleukines), synthetic 
low molecular weight compounds (eg, Levamisole), chemically modified nucleotides, 
polysaccharides from fungi (eg, Lentinan), and, especially in Europe and Asia, some 
plant extracts, are also used for the same purpose.
Many medicinal plant products have been reported to show immunomodulatory 
effects, such as barberin, boswellic acid, aristolochic acid, cichoric acid, and plumbagin.2 
Natural coumarinolignoids are also among the biologically active compounds which 
have shown promising immunomodulatory activity affecting both cell mediated 
and humoral immune response.3–5 Cleomiscosins are the natural coumarinolignoids 
extracted from an annual herb Cleome viscosa (syn. C. icosandra), a common weed 
of the family Capparidaceae and they have been used in the traditional systems of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Indian medicine. Considerable phytochemical work on 
different parts of this plant have been studied well.3–5 These 
are newly identified class of natural products in which a 
lignan group (C6C3 unit) is linked with a coumarin moiety 
through a dioxane bridge.5 Coumarinolignoids belong to the 
cycloalkylpropanoic acid class of compounds. Attachment of 
a phenylpropane unit with a polyphenolic compound through 
a dioxin bridge was earlier witnessed in the flavono-lignoid, 
silybin, xanthono-lignoid, and kielcorin.5 Cleomiscosins are 
the members of coumarino-lignoids and represent a new class 
of lignans called coumarinolignans. The isolated compounds 
showed immunomodulatory effect on Swiss albino mice, 
weighing 16–21g with LD50 value .100 µM/L for racemic 
mixture of three cleomiscosin molecules viz., A, B, and C.4
In the present study, we screen out potential anti-inflam-
matory and immunomodulatory compound cleomiscosin-B 
from the isolated racemic mixture of three cleomiscosin 
isoforms through quantitative structure activity relationship 
(QSAR) and molecular docking studies. On the basis of 
binding affinity energy, possible immunomodulatory recep-
tors were identified. For the structural activity relationship, a 
multiple linear QSAR regression model was developed which 
successfully establishes the immunomodulatory activity of 
coumarinolignoids in accord with the in vivo experimental 
data.4 QSAR modeling also furnishes the activity depen-
dent structural descriptors and predicts the effective dose 
of other derivatives, thereby suggesting the possible toxic-
ity range. The relationship correlating measure of QSAR 
model was 99% (R2 = 0.99) and predictive accuracy was 
96% (RCV2 = 0.96). Druggability of studied compounds was 
evaluated using Lipinsky’s ‘Rule of Five’ and in silico ADME 
analysis through bioavailability filters. QSAR studies indi-
cate that dipole moment, steric energy, amide group count, 
lambda max UV-visible, and molar refractivity correlate well 
with anti-inflammatory and immunomodulatory activity. 
These results could offer useful references for understand-
ing mechanisms and directing the molecular design of lead 
compounds with improved immunomodulatory activity.
Materials and methods
isolation and in vivo immunomodulatory 
activity of coumarinolignoids
The chemical and structural determination of studied 
coumarinolignoid derivatives from C. viscosa have been 
studied using IR Spectra and nuclear magnetic resonance 
(NMR) techniques. Isolation and in vivo anti-inflammatory 
and immunomodulatory activity of coumarinolignoids 
from C. viscosa seeds have been carried out in the past by 
Bawankule et al.4 Anti-inflammatory and immunomodulatory 
activity of coumarinolignoids was studied in a lipopolysac-
charide- (LPS) induced toxicity model in Swiss albino mice, 
  weighing 16–21 g. Proinflammatory mediators such as cytok-
ines, interleukin-6 (IL-6), or tumor necrosis factor-α (TNF-α) 
and nitric oxide (NO) were estimated from culture superna-
tant obtained from peritoneal macrophages stimulated by LPS 
and anti-inflammatory mediator IL-4 was estimated from 
culture supernatant obtained from spleenocytes stimulated 
by concavalin-A (Con-A). For further confirmation, expres-
sions of inflammatory mediators from serum and mortality 
rate were studied in an LPS-induced toxicity model in mice. 
Proinflammatory mediator’s expression was significantly 
decreased in the treatment group in a dose-dependent man-
ner, whereas the anti-inflammatory mediator expression was 
significantly increased at 10 mg/kg treatment. Mortality rate 
was also significantly reduced in the treatment group in the 
LPS-induced toxicity model.4
structure cleaning, optimization,  
and molecular docking
The structures of coumarinolignoid derivatives were con-
structed using the Scigress Explorer v7.7.0.47 (Fujitsu Ltd., 
Tokyo, Japan) workspace module. The optimization of the 
cleaned molecules was done through MO-G computational 
application that computes and minimizes an energy related 
to the heat of formation. The MO-G computational applica-
tion solves the Schrodinger equation for the best molecular 
orbital and geometry of the ligand molecules. The augmented 
Molecular Mechanics (MM2/MM3) parameter was used for 
optimizing the molecules up to its lowest stable energy state. 
This energy minimization is done until the energy change is 
less than 0.001 kcal/mol or the molecules are updated almost 
300 times. However, the chemical structures of known drugs 
were retrieved through the PubChem compound database 
at NCBI (http://www.pubchem.ncbi.nlm.nih.gov). Crystal-
lographic 3D structures of Human’s target proteins were 
retrieved through Brookhaven protein databank (http://www.
pdb.org). The valency and hydrogen bonding of the ligands as 
well as target proteins were subsequently satisfied through the 
Workspace module. Hydrogen atoms were added to protein 
targets for correct ionization and tautomeric states of amino 
acid residues such as His, Asp, Ser, and Glu. Molecular dock-
ing of the drugs and the isolated coumarinolignoid derivatives, 
especially cleomiscosin molecules (A, B, and C), with the 
immunomodulatory receptors was done using the Fast-Dock-
Manager and Fast-Dock-Compute engines available with the 
Project-leader module of Scigress Explorer (7.7.0.47; Fujitsu Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Ltd., Tokyo, Japan). For automated docking of ligands into 
the active sites we used genetic algorithm with a fast and 
simplified Potential of Mean Force (PMF) scoring scheme.6–7 
PMF uses atom types which are similar to the empirical force 
fields used in Mechanics and Dynamics. A minimization is 
performed by the Fast-Dock engine which uses a Lamarkian 
genetic algorithm (LGA) so that individuals adapt to the sur-
rounding environment. The best fits are sustained through 
analyzing the PMF scores of each chromosome and assigning 
more reproductive opportunities to the chromosomes having 
lower scores. This process repeats for almost 3,000 generations 
with 500 individuals and 100,000 energy evaluations. Other 
parameters were left to their default values. Structure-based 
screening involves docking of candidate ligands into protein 
targets, followed by applying a PMF scoring function to esti-
mate the likelihood that the ligand will bind to the protein with 
high affinity or not.7–8
selection of chemical descriptors  
for QsAr modeling
For identifying the immunomodulatory activity of the cou-
marinolignoid derivatives, QSAR study was performed. 
A total of 52 chemical properties (descriptors) were used 
for QSAR model development. A total of 61 drugs were 
involved and lethal dose was considered as the biological 
activity parameter of the compounds. Forward feed multiple 
linear regression mathematical expression was then used to 
predict the biological response of other derivatives. QSAR 
analysis is a mathematical procedure by which the chemi-
cal structures of molecules is quantitatively correlated with 
a well defined parameter, such as biological activity or 
chemical reactivity. For example, biological activity can be 
expressed quantitatively as in the concentration of a substance 
required to give a certain biological response. Additionally, 
when physicochemical properties or structures are expressed 
by numbers, one can form a mathematical relationship, or 
quantitative structure-activity relationship, between the two. 
The mathematical expression can then be used to predict the 
biological response of other chemical structures. QSAR’s 
most general mathematical form is:
Activity = f (physiochemical properties and/or 
  structural properties)
A QSAR model attempts to find consistent relationships 
between the variations in the values of molecular properties 
and the biological activity for a series of compounds which 
can then be used to evaluate properties of new chemical 
entities.9,23
Before the novel compounds can be used as potential 
drugs, the prediction of toxicity/activity ensures the cal-
culation of risk factors associated with the administration 
of that particular drug. A QSAR model ultimately helps in 
predicting these important parameters in the form of ED50 
or LD50 values. Some of the important chemical descriptors 
used in multiple linear regression analysis are: atom count 
(all atoms), atom count (carbon), atom count (hydrogen), 
atom count (oxygen), bond count (all bonds), conformation 
minimum energy (kcal/mole), connectivity index (order 0, 
standard), connectivity index (order 1, standard), connectiv-
ity index (order 2, standard), dipole moment (debye), dipole 
vector X (debye), dipole vector Y (debye), dipole vector Z 
(debye), electron affinity (eV), dielectric energy (kcal/mole), 
steric energy (kcal/mole), total energy (Hartree), group count 
(amine), group count (carboxyl), group count (ether), group 
count (hydroxyl), group count (methyl), heat of formation 
(kcal/mole), HOMO energy (eV), ionization potential (eV), 
lambda max UV-visible (nm), lambda max far-UV-visible 
(nm), LogP, LUMO energy (eV), molar refractivity, molecular 
weight, polarizability, ring count (all rings), size of smallest 
ring, size of largest ring, and solvent accessibility surface 
area (Å2).
In silico druggability and ADMe
For analyzing druggability, Lipinski’s rule of five pharma-
cokinetics filter was used as a drug likeness test.9 Briefly, 
this rule is based on the observation that most orally admin-
istered drugs have a molecular weight (MW) of 500 or less, 
a logP no higher than 5, five or fewer hydrogen bond donor 
sites, and 10 or fewer hydrogen bond acceptor sites (N and O 
atoms). In addition, the bioavailability of all derivatives or 
test compounds was assessed through topological polar 
surface area analysis. We calculated the polar surface area 
(PSA) by using termed topological PSA (TPSA), based on 
the summation of tabulated surface contributions of polar 
fragments (ChemAxon-Marvinview 5.2.6:PSA plugin).10 
Polar surface area (PSA) is formed by the polar atoms of 
a molecule. This descriptor was shown to correlate well 
with passive molecular transport through membranes and 
therefore allows prediction of transport properties of drugs 
and has been linked to drug bioavailability. Generally, 
passively absorbed molecules with a PSA . 140 Å2 are 
thought to have low oral bioavailability.11 Calculation of 
other important absorption, distribution, metabolism, and 
excretion (ADME) properties of studied compounds was 
done through QikProp software (version 3.2; Schrödinger, 
LLC, New York, NY).Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Results and discussion
chemical structure-activity  
relationship (sAr)
In the present work, 12 derivatives of natural coumarinoli-
gnoids were evaluated for their anti-inflammatory and immu-
nomodulatory activity through QSAR, ADME, and docking 
studies. Later results were compared with experimental in vivo 
activity data, which suggest that only three derivatives of 
coumarinolignoids (compound 1a, 1f, and 2a) have good 
anti-inflammatory and immunomodulatory activity. Results 
of the SAR study suggest in compound 1a (cleomiscosin-
A), the phenolic and alcoholic-OH groups in its molecule 
are responsible for its activity.3 The presence of a coumarin 
moiety based on other SAR studies on cleomiscosin-A (1a) 
has already been well established.3 Cleomiscosin-C (1f) has 
an extra -OMe group in the phenylpropanoid unit, and thus 
it showed less activity. It was found that the resonances for 
compound-1f were in good agreement with those for 1a, rather 
than those for 2a (cleomiscosin-B), especially in the chemical 
shifts for C-7’, C-8’, and C-9’, which were most affected by 
the structural difference between 1f and 2f. Compound 1f is 
a racemic compound and therefore has the same structural 
framework as 1a. Compound 2a (cleomiscosin-B) is the posi-
tion isomeric compound of 1a and shows striking resemblance 
with 1a in all its spectral properties, indicating a close structural 
similarity, thus become most active derivative. The two oxide 
linkages in compound 2a are at C-7 and C-8 as in 1a (Figures 
1–3). Later in vivo immunomodulatory biological activity of 
these compounds was tested on Swiss mice.4 Since in vivo 
activity was done on the racemic mixture of cleomiscosin A, 
B and C, compounds (compound 1a, 1f, and 2a), in the pres-
ent work we tried to explore the most active compound in the 
mixture based on QSAR modeling, molecular docking, and 
in silico ADME analysis. Results indicate that all compounds 
produce significant anti-inflammatory and immunomodulatory 
activity similar to that of the standard drug aristolochic acid. 
Compound 2a (cleomiscosin-B) exhibits strong anti-inflam-
matory and immunomodulatory activity, while compound 
1a (cleomiscosin-A) exhibits the least activity. In vivo dose-
dependent experimental data for immunomodulatory effect of 
studied compounds are summarized in Table 1.
Quantitative structure-activity 
relationship (QsAr) modeling
Structure activity relationship has been denoted by QSAR 
model showing significant activity-descriptors   relationship 
accuracy of 99% (R2 = 0.99) and activity prediction accu-
racy of 96% (RCV2 = 0.96). A total of 61 drugs were used 
for QSAR modeling against 52 chemical descriptors. Only 
five descriptors were found to be significant and seem to 
be responsible for in vivo immunomodulatory activity 
(Table 2). A forward feed multiple linear regression QSAR 
model was developed using leave-one-out approach for the 
prediction of biological activity of cleomiscosin molecules. 
Anti-inflammatory and immunomodulatory drugs fit well 
into this correlation, which intuitively seems very reason-
able. Results indicate that variations in stereochemistry 
do not markedly affect the binding energy of ligand and 
receptor. Therefore, we looked for a simpler descriptor for 
the prediction of biological in vivo activity for studied class 
of compounds. QSAR studies indicate that dipole moment, 
steric energy, amide group count, lambda max (UV-visible), 
and molar refractivity correlate well with biological activity 
(Table 2). The QSAR mathematical model equation derived 
through multiple linear regression method is given below, 
showing relationship between in vivo experimental activity 
(LD50) and dependent five chemical descriptors:
Predicted log LD50 (mg/kg) = −0.156436 * dipole moment 
(debye) −0.00118794 * steric energy (kcal/mole) +0.910351 * 
group count (amide) +0.0206362 * lambda max UV-visible 
(nm) −0.00834447 * molar refractivity −1.06753.
[RCV2 = 0.96 (96%) and R2 = 0.99 (99%)]
Since experimental in vivo activity was reported for 
racemic mixture of three cleomiscosin molecules A, B, and C 
(1a, 2a, and 1f) ie, 100 mg/kg (Table 1), we therefore aimed 
to predict the activity of each compound separately through 
QSAR modeling and identify the most active compound. 
We successfully developed the QSAR model for both anti-
inflammatory and immunomodulatory activity. More than 
50 known drugs with reported anti-inflammatory as well 
as immunomodulatory activity were included in the train-
ing data set for comparison and evaluation of prediction 
accuracy of QSAR model. Results showed that predicted 
activity of cleomiscosin molecules (A, B, and C) were 
comparable with experimental activity. Results indicate that 
cleomiscosin-B (2a) had higher immunomodulatory activity 
than cleomiscosin-C (1f) and cleomiscosin-A (1a). Moreover, 
based on the results of molecular docking, cleomiscosin-B 
showed much better binding energy with immunomodu-
latory receptors, and is therefore considered as the most 
active compound in the coumarinolignoids mixture. We also 
checked the compliance of isolated compounds to Lipinski’s Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Prototype-1
R2
R2
R1O
OR1
CH2OR
ROH2C
OMe
O
O O O
O O O
O
MeO
MeO
MeO
Prototype-2 
Derivative RR 1R 2 Name 
1a HHHCleomiscosin-A*
1b HM eH Monomethyl ether
1c HE tH Monoethyl ether
1d Ac Ac H Diacetate
1e Ac Et H Monoacetate
1f HHOMe Cleomiscosin-C*
2a HHHCleomiscosin-B*
2b HM eH Monomethyl ether
2c HE tH Monoethyl ether
2d Ac Ac H Diacetate
2e HHOH Hydroxy derivative
2f HHOMe Methoxy derivative
Figure 1 Molecular differences in different coumarinolignoids derivatives. Prototype 1 and 2 are showing fusion of coumarin moiety with the phenylpropanoid unit (c6c3). 
Bold face indicates active and isolated compounds. Asterisk indicates that compounds were isolated as racemic mixture.
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Figure 2 Molecular structure of the purified active natural coumarinolignoids isoforms 1a (Cleomiscosin-A), 1f (Cleomiscosin-C), and 2a (Cleomiscosin-B) isolated from 
the seeds of C. viscosa.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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rule-of-five for drug likeness (Table 3). Results indicate that 
isolated compounds follow most of the ADME properties, 
thus leading to a good drug candidate for anti-inflammatory 
and immunomodulatory activity (Table 4). This helped in 
establishing the pharmacological activity of these isolated 
novel compounds for their use as potential drugs. Moreover, 
when we calculated the topological polar surface area (TPSA) 
as a chemical descriptor for passive molecular transport 
through membranes, results showed higher TPSA of iso-
lated compounds than standard drugs but within   acceptable 
range (Table 3). TPSA allows for prediction of transport 
properties of drugs and has been linked to drug bioavail-
ability. Generally, it has been seen that passively absorbed 
molecules with a TPSA . 140 Å2 are thought to have low 
oral bioavailability.11 On the basis of bioavailability scores, 
we concluded that isolated compounds have marked immu-
nomodulatory activity but lower bioavailability as compared 
to standard drugs. Isolated compound cleomiscosin-B (2a) 
and cleomiscosin-C (1f) showed comparatively low TPSA 
than cleomiscosin-A (1a).
Binding affinity of coumarinolignoids  
for immunomodulatory receptors
The effect of coumarinolignoids when studied in Swiss 
albino mice for anti-inflammatory and immunomodulatory 
activity showed a significant decrease in the expression 
of pro-inflammatory mediators such as IL-6, TNF-α, and 
nitric oxide in a dose-dependent manner. Also the expres-
sion of immunomodulatory mediator IL-4 was found to 
increase with cleomiscosin A, C, and B (1a, 1f, and 2a) 
Diclofenac (CID: 3033)
Cleomiscosin (1a)
Cleomiscosin (2a)
Cleomiscosin (1f)
Distance RMS (Å)
Compd.
1a 2a 1f Diclofenac
1a 01 .612 1.1730 .7942
2a 1.612 01 .893 1.3895
1f 1.173 1.8930 1.390
Diclofenac0 .7942 1.3061 .390 0
Figure 3 superimposition of most favorable conformations of compounds 1a, 2a, 1f, and diclofenac docked into binding site of cOX-2 receptor showing common 
pharmacophore ring structure.
Table  1  In  vivo  experimental  anti-inflammatory  and  immuno-
modulatory activity data of isolated mixture of cleomiscosin A, B, 
and c molecules
Treatment (in vivo oral dose) Response % Mortality*
Vehicle control  0  0/6
LPs control  100 6/6
coumarinolignoids (10 mg/kg) + LPs  17  1/6
coumarinolignoids (30 mg/kg) + LPs  67  4/6
coumarinolignoids (100 mg/kg) + LPs  50 3/6
Note: * = no. of female swiss albino mice (n = 6).Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 2 comparison of experimental and predicted in vivo activity data calculated through QSAR modeling based on the five most 
highly correlated chemical descriptors
Drug/compound Exp LD50 
(mg/kg)
Exp 
log LD50
Pred 
log LD50
Dipole moment 
(debye)
Steric energy 
(kcal/mol)
Group count 
(amide)
Lambda max 
UV-visible 
(nm)
Molar 
refractivity
Aristolochic acid 81 1.91 1.91 9.48 32.21 0 252.40 85.12
Azimexon 170 2.23 2.22 3.86 509.14 1 194.44 51.20
Bowellic acid 5000 3.70 3.70 2.61 114.53 0 311.39 133.70
ciamexon 130 2.11 2.15 4.02 251.32 0 223.73 56.96
cichoric acid 1750 3.24 3.24 4.50 −12.68 0 287.34 112.13
emetin 32 1.51 1.50 1.91 39.04 0 197.41 139.75
imemixon 150 2.18 2.16 5.94 134.83 0 220.48 28.47
isopteropodin 162 2.21 2.22 5.07 40.63 1 196.12 99.27
Levamisol 180 2.26 2.26 4.12 27.81 0 218.54 60.74
curcumin 2000 3.30 3.71 3.74 5.20 0 302.16 103.42
celecoxib 2000 3.30 1.39 4.29 52.90 0 191.16 90.98
calanolide 800 2.90 3.17 4.97 8.49 0 285.83 104.11
Acetylsalicylic 200 2.30 2.47 1.58 5.49 0 201.60 43.95
cortisol 5120 3.71 2.07 3.42 75.13 0 221.89 97.49
cyclophosphamide 200 2.30 2.39 4.01 −10.67 0 220.69 58.48
cleomiscosin-A 100* 2.00 1.50 6.28 5.29 0 211.49 97.37
cleomiscosin-B 1.44 4.27 5.87 0 193.71 97.37
cleomiscosin-c 1.49 5.18 5.76 0 205.71 103.84
Diclofenac 2.59 2.30 1.02 51.40 0 204.28 75.46
*Anti-inflammatory and immunomodulatory activity data for racemic mixture of cleomiscosin-A, B, and C.
Table 3 compliance of compounds with computational parameters of drug likeness
S No. Compd TPSA (Å2) Molecular weight  Log P H-bond donors 
(OH group) 
H-bond acceptors 
(O atom) 
No. of rule of 
five violations
  1. Diclofenac 49.33 296.152 3.965 0 2 0
  2. 1a 91.29 386.357 1.822 2 8 0
  3. 1b 74.22 400.384 1.853 1 8 0
  4. 1c 83.45 414.411 2.196 1 8 0
  5. 1d 106.59 502.431 2.276 0 12 2
  6. 1e 63.22 472.448 2.596 0 10 0
  7. 1f 83.45 416.384 1.569 2 9 0
  8. 2a 83.45 386.357 1.821 2 8 0
  9. 2b 72.45 400.384 1.853 1 8 0
10. 2c 72.45 414.411 2.196 1 8 0
11. 2d 44.76 502.431 2.276 0 12 2
12. 2e 103.68 402.357 1.537 3 9 0
13. 2f 92.68 416.384 1.569 2 9 0
14. 3 101.91 460.48 2.554 0 9 0
15. 4 112.91 448.469 1.886 1 9 0
16. 5 106.91 386.357 1.722 2 8 0
  administration. The expressions of inflammatory   mediators 
from serum and mortality rate were studied in an LPS-
induced acute inflammation model.4 We predicted the 
orientations and binding affinities of caumarolignoids 
with proinflammatory proteins and others with the aim 
of determining which units interact better. We know that 
the innate immune recognition is mediated by a structur-
ally diverse set of receptors that belong to several dis-
tinct protein families. Among them are humoral proteins 
circulating in the plasma, endocytic receptors expressed 
on the cell   surface, and signaling receptors that can be 
expressed either on the cell surface or intracellularly.12 The 
proinflammatory cytokines such as IL-1, IL-6, or TNF-α 
have been found to contribute to a variety of inflamma-
tory condition such as ischemic tolerance,13 rheumatoid 
arthritis,14 nephritis,15 and liver diseases.16 Nitric oxide 
generated through inducible NO synthase (iNOS) enzy-
matic activity has been found to be participating in various Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 4 compliance of compounds with computational parameters of ADMe
Principal  
descriptors
Levamisole Aristolochic acid Cleomiscosin-A Cleomiscosin-B Cleomiscosin-C (Range 95%  
of drugs)
solute molecular  
weight
204.289 341.276 386.357 386.357 416.384 (130.0/725.0)
solute dipole  
moment (D)
5.344 14.344* 8.366 10.631 7.109 (1.0/12.5)
solute total  
sAsA
427.221 503.667 591.932 598.957 619.895 (300.0/1000.0)
solute hydrophobic  
sAsA
161.747 156.135 233.265 223.883 282.155 (0.0/750.0)
solute hydrophilic  
sAsA
26.205 164.026 177.359 163.462 173.297 (7.0/330.0)
solute carbon  
pi sAsA
191.048 183.506 181.307 211.612 164.443 (0.0/450.0)
solute weakly  
polar sAsA
48.22 0 0 0 0 (0.0/175.0)
solute molecular  
volume (A^3)
698.974 900.195 1084.061 1076.777 1161.989 (500/2000)
solute vdW  
Polar sA (PsA)
17.591 110.831 117.094 111.88 125.462 (7.0/200.0)
solute no. of  
rotatable bonds
0 3 5 5 6 (0.0/15.0)
solute as donor –  
hydrogen bonds
0 1 2 2 2 (0.0/6.0)
solute as acceptor –  
hydrogen bonds
2 5.25 7.95 7.95 8.7 (2.0/20.0)
solute globularity  
(sphere = 1)
0.892 0.895 0.862 0.848 0.862 (0.75/0.95)
solute ionization  
potential (eV)
8.874 9.345 8.951 8.835 8.854 (7.9/10.5)
solute electron  
affinity (eV)
0.381 2.484* 1.546 1.393 1.681 (−0.9/1.7)
Polarizability  
(angstroms^3)
23.643 M 29.698 M 35.751 35.749 38.067 (13.0/70.0)
log P for  
hexadecane/gas
6.610 M 9.430 M 11.315 11.330 11.880 (4.0/18.0)
log P for  
octanol/gas
8.972 17.260 M 19.997 20.480 20.872 (8.0/35.0)
log P for water/gas 4.212 9.269 M 13.240 13.369 13.683 (4.0/45.0)
log P for  
octanol/water
3.108 2.395 1.723 1.798 1.913 (−2.0/6.5)
log s for aqueous  
solubility
−3.476 −3.281 −3.553 −3.664 −3.613 (−6.5/0.5)
log s – conformation 
independent
−3.064 −5.011 −4.962 −4.962 −5.262 (−6.5/0.5)
log K hsa serum  
protein binding
0.112 −0.194 −0.12 −0.15 −0.099 (−1.5/1.5)
log BB for  
brain/blood
0.462 −0.982 −1.329 −1.252 −1.352 (−3.0/1.2)
no. of primary  
metabolites
2 2 5 5 6 (1.0/8.0)
Predicted cns  
activity
++ – – – – –2 (inactive), 
+2 (active)
herg K+ channel  
blockage: log ic50
−4.198 −2.296 −4.627 −4.997 −4.545 (concern 
below −5)
Apparent caco-2  
permeability (nm/sec)
5589 69 206 279 225 (,25 poor, 
.500 great)
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Table 4 (Continued)
Principal  
descriptors
Levamisole Aristolochic acid Cleomiscosin-A Cleomiscosin-B Cleomiscosin-C (Range 95%  
of drugs)
Apparent MDcK  
permeability (nm/sec)
5839 35 89 124 98 (,25 poor, 
.500 great)
QP log Kp for skin  
permeability
−3.392 −3.608 −3.669 −3.307 −3.558 (−8.0 to −1.0, 
Kp in cm/hr)
Jm, max transdermal  
transport rate
0.028 0.058 0.023 0.041 0.028 (micrograms/
cm^2-hr)
Lipinski rule of 5  
violations
0 0 0 0 0 (maximum is 4)
Jorgensen rule of 3  
violations
0 0 0 0 0 (maximum is 3)
% human oral  
absorption in gi (±20%)
100 74 78 81 80 (,25% is 
poor)
Qual. model for  
human oral absorption
high high high high high (.80% is high)
Note: *indicates a violation of the 95% drug likeness range.
immune and inflammatory reactions. Immunomodulatory 
cytokines like IL-4, IL-10, and IL-13 are responsible for 
inhibiting the proinflammatory signaling and hence reduce 
inflammation. Recent advances in the studies of innate 
immunity have yielded better understanding of inflam-
matory mechanisms.
Toll-like receptors (TLRs) have been found to recog-
nize and respond to the moieties related to tissue injury and 
microbial infections.17 TLRs are mediators of various cell 
mediated and humoral immune response caused by differ-
ent agents or TLR specific ligands. Different TLRs have 
been found to respond to variety of pathogen-associated 
molecular pattern (PAMP) such as microbial agents, viral 
proteins, RNA, CpG DNA, bacterial lipopolysaccharides 
(LPS), and peptidoglycan. Signaling through TLRs results 
in inflammatory reactions mediated by various cytokines 
such as TNF-α, IL-6, IL-8, and IL-1ß. The inhibitors of 
TLR mediated signaling of inflammatory reactions are 
the decoy receptors, signaling inhibitors, and immu-
nomodulatory cytokines (IL-4, IL-10, and IL-13).13–18 
Additionally, cluster of differentiation (CD) plays a very 
important role in the various immunological cascades of 
reactions and acts as a costimulatory signaling molecule 
for the activation of several lymphocytes. This activity is 
responsible for producing numerous immune responses 
such as production of T-helper cells, T-cytotoxic cells, 
macrophage activation, and antibody production.19–22 
Results of molecular docking were comparable with the 
experimental results,4 which suggest that proinflamma-
tory mediator expression was significantly decreased in 
the coumarinolignoids treatment group in dose dependent 
manner. This suggests that oral administration of cou-
marinolignoids inhibits the proinflammatory mediators 
and enhances the production of the immunomodulatory 
mediator (Table 5; Figures 4–6).
Conclusion
Molecular modeling calculations accompanied by in vivo 
experimental data on Swiss albino mice were used to predict 
potential immunomodulatory compounds among natural cou-
marinolignoids namely, cleomiscosin-A (1a), cleomiscosin-C 
(1f), and cleomiscosin-B (2a) isolated from C. viscosa seeds. 
The obtained results indicate that all studied compounds pos-
sess significant anti-inflammatory and immunomodulatory 
activity after oral administration and that cleomiscosin-B 
possess higher immunomodulatory activity comparable to 
standard drugs eg, Levamisole and cyclophosphamide. The 
QSAR analysis established the immunostimulatory activity 
of the cleomiscosin molecules in a dose dependent manner, 
which is in accord with the in vivo data. Results of molecu-
lar docking combined with in vivo data for inhibition of the 
human proinflammatory mediators suggest that compound 
cleomiscosin-B is preferentially more active than others with 
strong binding affinity to most of the immuno-modulatory 
receptors.
Table  5  Molecular  docking  based  identification  of  potential 
immunomodulatory targets of cleomiscosin molecules
Coumarinolignoids Potential target
cleomiscosin A (1a) TLr-4
cleomiscosin B (2a) inOs, cOX-2, cD14, iKK ß
cleomiscosin c (1f) cD86, cOX-1Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 4 Binding affinity of cleomiscosin A, B, and C against toll-like receptors (TLRs). Docking scores (kcal/mol) in negative are acceptable.
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Figure 5 Binding affinity of cleomiscosin A, B, and C with various cluster of differentiation molecules (CD molecules) and T-cell receptor proteins. Negative docking scores 
(kcal/mol) are acceptable.
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Figure 6 Binding affinity of cleomiscosin A, B, and C with various immune reaction cascade proteins and inducible nitric oxide synthase (iNOS) protein. Negative docking 
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Appendix
Appendix 1 List of training data set of drugs/compounds used 
in QSAR modeling. Anti-inflammatory and immuno-stimulatory 
drugs/compounds.  Asterisk  mark  indicates  that  compounds 
retrieved from Pubchem database, ncBi, UsA (www.pubchem.
ncbi.nlm.nih.gov) 
S No. Compound Reference*  
(PubChem ID)
  1. Aristolochic acid ciD: 2236
  2. cichoric acid  ciD: 5281764
  3. indometacin ciD: 3715
  4. Plumbagin ciD: 10205
  5. Berberine ciD: 2353
  6. emetin ciD: 10219
  7. isopteropodin ciD: 122813
  8. Bowellic acid  ciD: 168928
  9. gelsemin ciD: 6713959
10. Azimexon ciD: 47294
11. ciamexon ciD: 71759
12. imemixon ciD: 68791
13. Methyl inosin monophasphate  ciD: 454158
14. Diethyl dithiocarbamate ciD: 28343
15. Levamisol ciD: 26879
16. Urushiol ciD: 5478166
17. Ubiquinone  ciD: 4462
18. saikosaponin ciD: 11968912
19. Tabernanthine ciD: 442136
20. helenalin ciD: 23205
Appendix 2 List of training data set of drugs/compounds used in 
QsAr modeling. immuno-suppressive drugs/compounds
S No. Drug/compound Reference
  1. 5-Fluorouracil Drug bank database
  2. cytarabine hydrochloride Drug bank database
  3. Busulfan Drug bank database
  4. Thalidomide Drug bank database
  5. saikosaponin http://articles.directorym.com/
chai_hu_-a853270.html
  6. Methyl cellosolve Drug bank database
  7. Butenolide Moniliformin and butenolide: 
effect on mice of high-level, 
long-term oral intake pdf
  8. Methoxyacetic acid Drug bank database
  9. carboxylic acid http://www.maximpowercorp.
com/_pdf/deerland%20project/
alberta%20environment/
ePeAdeerlandapplication_
appendix%20g_16oct07.pdf
10. Azodicarbonamide http://www.sciencelab.
com/xMsDs-
azodicarbonamide_F_c_c-
9922989
11. cyclophosphamide  
monohydrate
http://www.sciencelab.com/
xMsDs-cyclophosphamide_
monohydrate-9923635
(Continued)
Appendix 2 (Continued)
S No. Drug/compound Reference
12. gemcitabine/gemzar http://www.flexyx.com/g/
gemcitabine%20hcl.html
13. rapamycin (sirolimus) www.fermentek.co.il/MsDs/
rapamycin-MsDs.htm
14. Tacrolimus fujimycin Drug bank database
15. Melphalan Drug bank database
16. Dimethyl sulphate www.chembargains.com/
attachfile/msds-100234.doc
17. Thalidomide http://msds.chem.ox.ac.uk/Th/
thalidomide.html
18. radanil/benznidazol http://wisda.pharmazie.
uni-marburg. de/index.
html?http&&&wisda.pharmazie.
uni-marburg. de/dossier 
e.php?s _inn=benznidazol
19. Mizoribine http://www.msdshazcom.com/
web_docs/emd/doc/wcd00008/
wcd008a9.pdf
20. nitrosodimethyl urea http://hazard.com/msds/tox/f/
q140/q167.html
21. Azaserine http://www.msdshazcom.com/ 
WeB_DOcs/eMD/docs/
wcd0000b/wcd00b3d.pdf
22. Thiotepa http://wfldelearn.pssd.
com/binderview_Pss/
vault/001/001100.pdf. in the 
search for new anticancer 
drugs/sosnovsky g, Li sW
23. cytarabine hydrochloride http://msds.chem.ox.ac.uk/cY/
cytarabine_hydrochloride.html
24. cytarabine/cylocide http://www.labseeker.com/
chemicalbiotech/chem-
moreinfo. asp? catalog_ no 
=21384
25. cytoxan http://www.pfeist.net/ALL/
cytoxan.html
26. coformycin  
(deoxy-coformycin)
Purine metabolism in 
adenosine deaminase 
deficiency chapter authors:  
h Anne simmonds, A sahota, 
cF Potter, D Perrett,  
K hugh-Jones, Jg Watson
27. Thioinosine http://www.coleparmer.in/
catalog/msds/26568.htm
28. Leflunomide Drug bank database
29. Dibutyltin dichloride http://www.aladdin-reagent. 
com/msds/18969.htm
30. Azathioprine/imuran Drug bank
31. Mycophenolate mofetil Drug bank
32. Triamcinolone acetonide http://msds.chem.ox.ac.uk/Tr/
triamcinolone_acetonide.html
33. Lantadin/deflazacort http://www.labseeker.
com/cn/chemicalbiotech/
chemmoreinfo.asp?catalog_
no = 23945
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Dovepress 
Dovepress
185
QsAr model development
Appendix 2 (Continued)
S No. Drug/compound Reference
34. D-amethopterin hydrate/ 
D-methotrexate
http://www.aladdinreagent. 
com/msds/18362.htm
35. glimepiride http://wisda.pharmazie.  uni-
arburg.de/ 
http://www.labseeker.com/ 
chemical biotech/chem-moreinfo.
asp?catalog_no = 26445
36. gusperimus themerckindex.cambridgesoft.
com/themerckindex/
themerckindex/reversed/
M0004582.txt
37. Ledertrexate http://www.flexyx.com/L/
Ledertrexate.html
38. hexabutylditin oxide https://fscimage.fishersci.com/
msds/08596.htm
39. Tetrandrine Pharmacology and applications 
of chinese materia medica 
books. google.co.in/books? 
isbn 9810236921
40. Pheanthine http://www.chemdrug.
com/databases/13_0_
vwdsmntgaekxfsfg.html  
http://www.chemcas.com/msds/
cas/msds87/1263–79–2_v2.asp
41. Methotrexate Drug bank database
List of chemical descriptors  
used in QSAR modeling
  1. Atom count (all atoms)
  2.  Bond count (all bonds)
  3.  Conformation minimum energy (kcal/mole)
  4.  Connectivity index (order 0, standard)
  5.  Connectivity index (order 1, standard)
  6.  Connectivity index (order 2, standard)
  7.  Dipole moment (debye)
  8.  Dipole vector x (debye)
  9.  Dipole vector y (debye)
10.  Dipole vector z (debye)
11.  Electron affinity (ev)
12.  Dielectric energy (kcal/mole)
13.  Steric energy (kcal/mole)
14.  Total energy (Hartree)
15.  Group count (aldehyde)
16.  Group count (amide)
17.  Group count (amine)
18.  Group count (sec-amine)
19.  Group count (carbonyl)
20.  Group count (carboxyl)
21.  Group count (carboxylate)
22.  Group count (cyano)
23.  Group count (ether)
24.  Group count (hydroxyl)
25.  Group count (methyl)
26.  Group count (methylene)
27.  Group count (nitro)
28.  Group count (nitroso)
29.  Group count (sulfide)
30.  Group count (sulfone)
31.  Group count (sulfoxide)
32.  Group count (thiol)
33.  Heat of formation (kcal/mole)
34.  HOMO energy (eV)
35.  Ionization potential (eV)
36.  Lambda max visible (nm)
37.  Lambda max UV-visible (nm)
38.  Lambda max far-UV-visible (nm)
39.  Lambda max far-UV-visible (nm)
40.  Log P
41.  LUMO energy (eV)
42.  Molar refractivity
43.  Molecular weight
44.  Polarizability
45.  Ring count (all rings)
46.  Size of smallest Ring
47.  Size of largest Ring
48.  Shape index (basic kappa, order 1)
49.  Shape index (basic kappa, order 2)
50.  Shape index (basic kappa, order 3)
51.  Solvent accessibility surface area (angstromsquare)
52.  Formal charge
Details of some important 
descriptors
  1.    Molecular formula (MF): The molecular formula of 
the molecule.
  2.    Molecular weight (MW): The molecular weight of 
the molecule. 
  3.  Log P: The octanol-water partition coefficient.
  4.    Solvent accessible surf area (SASA): The molecular 
surface area accessible to a solvent molecule.
  5.    Polarizability (P): The molecule’s average alpha 
polarizability.
  6.    Shape index order 3 (SI3): A topological index quan-
tifying the shape of a chemical sample. The shape index 
of order 3 (Kappa 3) quantifies the degree of branching 
toward the center of the   chemical sample.Drug Design, Development and Therapy
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  7.    Shape index order 2 (SI2): A topological index quan-
tifying the shape of a chemical sample. The shape index 
of order 2 (Kappa 2) quantifies the degree of linearity or 
star-likeness of the chemical sample.
  8.    Shape index order 1 (SI1): A topological index quan-
tifying the shape of a chemical sample. The shape index 
of order 1 (Kappa 1) quantifies the number of cycles in 
the chemical sample.
  9.    Largest ring size (LRS): The number of atoms forming 
the largest ring in the chemical sample, or 0 if the chemi-
cal sample contains no ring of size 12 or less.
10.    Smallest ring size (SRS): Information about rings pres-
ent in the compound. Rings with more than 12 atoms 
are ignored. The number of atoms forming the smallest 
ring in the compound, or 0 if the compound contains no 
ring of size 12 or less.
11.    Ring count (RC): The number of rings present in 
the compound. Rings with more than 12 atoms are 
ignored. The number of rings with 12 or fewer atoms 
(All = all aromatic, small, 5-membered, 5-membered 
aromatic, 6-membered, 6-membered aromatic, large, 
large aromatic).
12.    Molar refractivity (MR): The molar refractivity of 
the compound.
13.    LUMO energy: The energy gained when an electron 
is added to the lowest unoccupied molecular orbital 
(LUMO).
14.    Lambda max far-UV-visible (LMFUV): The maxi-
mum absorption line in the far UV-visible spectrum 
(150–1000 nm).
15.    Lambda max-UV-visible (LMUV): The maxi-
mum absorption line in the UV-visible spectrum 
(190–1000 nm).
16.    Ionization potential (IP): The energy required to remove 
an electron from a molecule in its ground state.
17.    HOMO energy: The energy required to remove an 
electron from the highest occupied molecular orbital 
(HOMO).
18.    Heat of formation (HF): The energy released or used 
when a molecule is formed from elements in their stan-
dard states.
19.    Conformation minimum energy (CME): Energy calcu-
lated for an optimized conformation of the compound.
20.    Formal charge (FC): The net positive or negative 
charge on the molecule. Atom count (AC): The number 
of atoms.
21.    Bond count (BC): The number of bonds. Weak and 
ionic bonds are ignored.